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Introduction
Mitochondria are dynamic organelles that undergo continu-
ous remodeling through fusion and fission events. Conserved 
protein machineries mediate fusion and fission of mitochon-
drial membranes (Cerveny et al., 2007; Hoppins et al., 2007; 
Westermann,  2008).  The  dynamin-related  GTPase  OPA1, 
which  resides  in  the  mitochondrial  intermembrane  space,   
is involved in inner membrane fusion, in the regulation of 
mitochondrial  cristae  morphology,  and  in  protecting  cells 
from apoptosis (Olichon et al., 2003; Griparic et al., 2004; 
Frezza et al., 2006; Meeusen et al., 2006; Lenaers et al., 2009). 
Mutations in OPA1 cause dominant optic atrophy, a progres-
sive neurological disease characterized by degeneration of 
the  retinal  ganglion  cells  and  atrophy  of  the  optic  nerve 
(Amati-Bonneau et al., 2009). Mitochondria contain various 
OPA1 isoforms that arise from alternative splicing and proteo-
lytic  processing  events  at  two  sites,  S1  and  S2,  generating 
shorter isoforms (Delettre et al., 2001; Ishihara et al., 2006).
M
itochondrial fusion depends on the dynamin-
like  guanosine  triphosphatase  OPA1,  whose 
activity  is  controlled  by  proteolytic  cleavage. 
Dysfunction  of  mitochondria  induces  OPA1  processing 
and  results  in  mitochondrial  fragmentation,  allowing   
the selective removal of damaged mitochondria. In this 
study, we demonstrate that two classes of metallopepti-
dases regulate OPA1 cleavage in the mitochondrial inner 
membrane:  isoenzymes  of  the  adenosine  triphosphate 
(ATP)–dependent  matrix  AAA  (ATPase  associated  with 
diverse cellular activities [m-AAA]) protease, variable as-
semblies of the conserved subunits paraplegin, AFG3L1 
and  -2,  and  the  ATP-independent  peptidase  OMA1. 
Functionally redundant isoenzymes of the m-AAA protease 
ensure the balanced accumulation of long and short   
isoforms of OPA1 required for mitochondrial fusion. The 
loss  of  AFG3L2  in  mouse  tissues,  down-regulation  of 
AFG3L1 and -2 in mouse embryonic fibroblasts, or the 
expression of a dominant-negative AFG3L2 variant in 
human cells decreases the stability of long OPA1 iso-
forms and induces OPA1 processing by OMA1. More-
over,  cleavage  by  OMA1  causes  the  accumulation  of 
short OPA1 variants if mitochondrial DNA is depleted or 
mitochondrial activities are impaired. Our findings link 
distinct  peptidases  to  constitutive  and  induced  OPA1 
processing and shed new light on the pathogenesis of 
neurodegenerative disorders associated with mutations 
in m-AAA protease subunits.
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Results
AFG3L1 and -2 are required for 
mitochondrial fusion
We used RNAi in MEFs to down-regulate m-AAA protease 
subunits individually or in combination. Immunoblotting re-
vealed effective depletion of AFG3L1 and -2 and paraplegin 
(Fig. 1 A). Mitochondrial morphology was monitored by fluor-
escence microscopy in cells cotransfected with a mitochondri-
ally  targeted  DsRed  variant.  Neither  paraplegin-depleted 
mitochondria nor mitochondria from Spg7
/ MEFs showed 
morphological abnormalities (Fig. S1 and not depicted). Simi-
larly, mitochondria of cells transfected with either Afg3l1- or 
Afg3l2-specific siRNA appeared largely normal in morphology 
(Fig. 1, B and C). However, concomitant down-regulation of 
both  subunits  caused  fragmentation  of  the  mitochondrial   
network in 80% of the cells (Fig. 1, B and C). Examination   
of these cells by electron microscopy revealed a severe distur-
bance of the mitochondrial ultrastructure (Fig. 1 D). Lamellar 
cristae were either completely absent or severely reduced in 
number in cells lacking AFG3L1 and -2, whereas the structure 
of cristae was not significantly affected upon down-regulation 
of AFG3L1 or -2 (Fig. 1 D). These findings reveal overlapping 
activities of AFG3L1 and -2 and demonstrate an essential role 
of the m-AAA protease for the ultrastructure of mitochondria.
An impaired fusion or increased fission may cause frag-
mentation  of  the  mitochondrial  network  in  the  absence  of 
AFG3L1 and -2. To distinguish between these possibilities, we 
transfected interfered cells with a dominant-negative variant of 
the fission component DRP1, DRP1
K38A. In agreement with pre-
vious observations (Smirnova et al., 1998; James et al., 2003), 
expression of DRP1
K38A impaired fission and resulted in the 
elongation of mitochondrial tubules as the result of ongoing fu-
sion (Fig. 2, A and B). In contrast, cells lacking AFG3L1 and -2 
maintained  punctiform  mitochondria  upon  expression  of 
DRP1
K38A, strongly suggesting that the organelles are unable to 
fuse. As independent evidence, we found that cells interfered 
for Afg3l2 and -1 did not form a highly interconnected network 
when exposed to low concentrations of cycloheximide (CHX; 
Fig. 2, C and D), indicating that they have lost the ability to 
undergo stress-induced mitochondrial hyperfusion (SIMH), which 
is an adaptive response against stress (Tondera et al., 2009). 
Therefore, we conclude that the fusion of mitochondrial mem-
branes depends on AFG3L1 and -2.
The m-AAA protease controls the stability 
of L-OPA1
OPA1 regulates both mitochondrial fusion and cristae mor-
phogenesis (Lenaers et al., 2009). MEFs express mainly two 
alternative transcripts of OPA1, variants 1 and 7, which are 
cleaved, resulting in the accumulation of five OPA1 forms: 
two long (a and b) and three short isoforms (c–e; Ishihara   
et al., 2006; Duvezin-Caubet et al., 2007). Down-regulation of 
individual subunits of the m-AAA protease isoenzymes did 
not reproducibly affect the processing of OPA1 (Fig. 3 A). 
However, the concomitant loss of AFG3L1 and -2 significantly 
affected the accumulation of OPA1 variants (Fig. 3 A): the 
A combination of long and short OPA1 isoforms is re-
quired for mitochondrial fusion (Song et al., 2007), pointing to 
a crucial regulatory role of OPA1 processing. Roughly equi-
molar concentrations of long and short isoforms of OPA1 are 
formed under normal conditions. However, low mitochondrial 
ATP levels, the dissipation of the membrane potential across the 
inner membrane (m), or apoptotic stimuli induce OPA1 cleav-
age, resulting in the loss of long isoforms (Duvezin-Caubet   
et al., 2006; Ishihara et al., 2006; Baricault et al., 2007). Various 
proteases in the inner membrane have been linked to the pro-
cessing  of  OPA1.  The  intermembrane  space  AAA  (ATPase   
associated with diverse cellular activities) protease YME1L1 
regulates OPA1 cleavage at S2, which is only present in a subset   
of OPA1 variants (Griparic et al., 2007; Song et al., 2007).   
Debate exists about the protease cleaving OPA1 at S1, as both 
the rhomboid protease PARL (presenilin-associated rhomboid-
like protein) and the matrix AAA (m-AAA) protease, an oligo-
meric ATP-dependent metallopeptidase in the inner membrane, 
have been proposed to be involved in OPA1 processing (Cipolat 
et al., 2006; Ishihara et al., 2006). However, normal OPA1 pro-
cessing in mouse embryonic fibroblasts (MEFs) lacking PARL 
or the m-AAA protease subunit paraplegin raised doubts about 
the  role  of  either  protease  for  OPA1  processing  in  vivo   
(Duvezin-Caubet et al., 2007).
Notably, human and murine mitochondria possess dif-
ferent  m-AAA  protease  isoenzymes,  which  differ  in  their   
subunit  composition  but  exert  at  least  partially  redundant   
activities (Koppen et al., 2007). Three homologous subunits 
are expressed in the mouse, AFG3L1 and -2 and paraplegin. 
Whereas paraplegin was exclusively detected in heterooligo-
meric  complexes  with  AFG3L1  and  -2,  homooligomeric 
complexes composed of AFG3L1 or -2 do exist. Therefore, 
functionally  redundant  isoenzymes  might  substitute  for  the 
loss of paraplegin and maintain OPA1 processing in the ab-
sence of paraplegin. A complementation study in yeast indeed 
demonstrated  functional  conservation  of  different  mammalian   
m-AAA  protease  isoenzymes  and  revealed  their  ability  to 
cleave  OPA1  expressed  heterologously  in  yeast  (Duvezin-
Caubet et al., 2007). This notwithstanding, they have been 
linked to different neurodegenerative diseases in human: mu-
tations in Spg7 encoding paraplegin cause a recessive form of 
hereditary spastic paraplegia, whereas heterozygous muta-
tions in Afg3l2 are responsible for a dominant form of spino-
cerebellar ataxia, SCA28 (Cagnoli et al. 2008. Annual meeting 
of  the American  Society  of  Human  Genetics. Abstr.  1501;   
DiBella et al. 2008. Annual meeting of the American Society 
of Human Genetics. Abstr. 216). It is presently unclear whether 
this reflects functional differences of m-AAA isoenzymes or 
results from a tissue-specific expression of m-AAA protease 
subunits (Koppen et al., 2007).
In this study, we have assessed the function of different 
m-AAA  isoenzymes  in  vivo  using  RNAi  and  demonstrate   
that OPA1 processing and mitochondrial fusion depend on 
AFG3L1 and -2. Moreover, we identify a novel peptidase in 
the inner membrane, OMA1, which mediates OPA1 process-
ing if m-AAA proteases are absent or mitochondrial activities 
are impaired.1025 Control of OPA1 by m-AAA protease and OMA1 • Ehses et al.
the loss of long OPA1 isoforms can account for the frag-
mentation of the mitochondrial network upon depletion of 
AFG3L1 and -2. To test this hypothesis, we assessed mito-
chondrial morphology after coexpression of Afg3l1 and -2 
siRNAs with a Flag-tagged version of OPA1 splicing variant 1 
(v1), in which the amino acid residues flanking the process-
ing  site  had  been  deleted  (v1S1;  Ishihara  et  al.,  2006).   
Mitochondrial morphology was also analyzed in AFG3L1- and 
long OPA1 isoforms were no longer detected, whereas short 
forms, mainly e, accumulated (Fig. 3 A). This shift was not 
significantly enhanced in Spg7
/ cells (Fig. 3 A). These results 
substantiate the overlapping activities of AFG3L1 and -2 and 
point to an impaired OPA1 processing in m-AAA protease–
depleted MEFs.
Both long and short OPA1 isoforms are necessary to 
support mitochondrial fusion (Song et al., 2007). Therefore, 
Figure 1.  Fragmentation of mitochondria in MEFs depleted of AFG3L1 and -2. (A) Immunoblot analysis of MEFs transfected with siRNAs directed against 
AFG3L1 and -2 and paraplegin or scrambled siRNA (Scr) using specific antisera recognizing paraplegin (Para), AFG3L1 (L1), AFG3L2 (L2), and the 70-kD 
subunit of complex II (CII). (B and C) Mitochondrial morphology in AFG3L1- and AFG3L2-deficient MEFs was visualized by expression of mito-DsRed, 
and nuclear DNA was stained with DAPI. >150 MEFs were scored in each experiment. Bars represent means ± SD of three independent experiments   
(**, P < 0.01). (D) Mitochondrial ultrastructure in MEFs transfected with scrambled or AFG3L1- or AFG3L2-specific siRNAs or siRNAs against AFG3L1 and -2. 
Representative transmission electron micrographs of mitochondria are shown. Bars: (B) 10 µm; (D) 0.2 µm.JCB • VOLUME 187 • NUMBER 7 • 2009   1026
of long OPA1 isoforms. Therefore, we directly monitored the 
efficiency of OPA1 processing in the absence of m-AAA prote-
ase subunits by expressing Flag-tagged v1 or v1S1 in MEFs 
(Ishihara et al., 2006). Down-regulation of AFG3L1 and -2 pro-
moted processing of v1 and led to the loss of long OPA1 forms 
(Fig. 3 C). v1S1 was present at severely decreased levels in cells 
lacking both m-AAA protease subunits, suggesting degradation 
of the OPA1 variant (Fig. 3 C). Indeed, if protein synthesis was 
inhibited by CHX, v1S1 was stable upon further incubation of 
control cells (Fig. 3 D). In contrast, v1S1 level decreased in 
the absence of AFG3L1 and -2 (Fig. 3 D), explaining the only 
AFG3L2-depleted MEFs expressing S-OPA1, a hybrid pro-
tein composed of a short form of OPA1 fused to the mitochon-
drial  target  sequence  of  apoptosis-inducing  factor  (Ishihara   
et al., 2006). We observed a partial but statistically significant 
restoration of a tubular network in m-AAA protease–deficient 
cells upon expression of v1S1 but not of S-OPA1 (Fig. 3 B), 
suggesting that the m-AAA protease regulates mitochondrial 
fusion via OPA1.
These findings link, for the first time, the function of 
AFG3L1 and -2 to the biogenesis of OPA1. Surprisingly, deple-
tion of AFG3L1 and -2 caused a loss rather than a stabilization 
Figure 2.  AFG3L1 and -2 are required for mitochondrial fusion. (A and B) Inhibition of fission does not restore a tubular network in the absence of AFG3L1 
(L1) and AFG3L2 (L2). Dominant-negative DRP1
K38A-HA and mito-DsRed were expressed in m-AAA protease–deficient MEFs, and mitochondrial morphology 
was assessed after 24 h. >200 cells were scored per experiment. (C and D) SIMH depends on AFG3L1 and -2. After depletion of AFG3L1 and -2, MEFs 
were incubated for 3 (C and D) and 6 h (D) in the presence of 1 µM CHX (+CHX) as indicated. >150 cells were scored for each experiment. Bars represent 
means ± SD of three independent experiments (**, P < 0.01). Bars, 10 µm.1027 Control of OPA1 by m-AAA protease and OMA1 • Ehses et al.
Figure 3.  Destabilization of long OPA1 isoforms in the absence of the m-AAA protease. (A) Immunoblot analysis of Spg7
+/+ and Spg7
/ MEFs depleted 
of AFG3L1 (L1) and AFG3L2 (L2) as indicated. Cells lysates were analyzed with antibodies directed against OPA1, AFG3L1 and -2 and, for control, 
the 70-kD subunit of complex II (CII). OPA1 isoforms are marked with a–e. (B) Mitochondrial morphology in AFG3L1/AFG3L2-deficient MEFs expressing 
OPA1 variants. Before depletion of AFG3L1 and -2, MEFs were transfected with plasmids encoding Flag-tagged OPA1 variants v1S1 or S-OPA1. >150 
cells were scored. Bars represent means ± SD of three independent experiments (*, P < 0.05). (C) Immunoblot analysis of AFG3L1/AFG3L2-deficient 
MEFs expressing Flag-tagged OPA1 splice variants 1 (v1) and 1S1 (v1S1). Cell lysates were analyzed 3 d after siRNA transfection by SDS-PAGE and   
immunoblotting using anti-Flag and anti–complex II antibodies. (D) Degradation of v1S1 in AFG3L1/AFG3L2-depleted MEFs. 2 d after siRNA transfection,   
cells were incubated for 6 h with 100 µg/ml CHX and analyzed as described in C. (E) Mitochondrial membrane potential in MEFs depleted of m-AAA 
protease subunits was analyzed with the fluorescent dye JC-1 and flow cytometry at 590 nm. Dissipation of the membrane potential with CCCP was used 
as a control. Relative intensities to cells transfected with scrambled RNAi (C) are shown. Data represent means ± SD of three independent experiments 
(**, P < 0.01). Para, paraplegin. (F) Oxygen consumption in Spg7
+/+ and Spg7
/ MEFs depleted of AFG3L1/AFG3L2 was measured under routine 
conditions and in the presence of oligomycin (OLG) and CCCP. Bars represent means ± SD of three independent experiments (*, P < 0.05; **, P < 0.01; 
***, P < 0.001).JCB • VOLUME 187 • NUMBER 7 • 2009   1028
lack ATPase activity and trap ATP (Weibezahn et al., 2003; 
Dalal et al., 2004; Augustin et al., 2009). We established stable 
HEK293 cell lines allowing the tetracycline-inducible expres-
sion of C-terminally tagged AFG3L2 variants. In contrast to 
mouse fibroblasts, human cells express only two m-AAA prote-
ase  subunits, AFG3L2  and  paraplegin  (Kremmidiotis  et  al., 
2001). Induction of AFG3L2 expression in the presence of tetra-
cycline resulted in an approximately twofold overexpression 
of AFG3L2 (Fig. 4 B). Although overexpression of AFG3L2 or 
AFG3L2
E575Q (PS) did not affect cell growth, cells expressing 
AFG3L2
E408Q  (WB)  showed  a  prominent  reduction  of  their 
growth rate (Fig. 4 A), indicating that AFG3L2
E408Q (WB) but 
not AFG3L2
E575Q  (PS)  exerts  a  dominant-negative  effect  on 
other m-AAA protease subunits.
Long OPA1 isoforms were destabilized in the presence of 
AFG3L2
E408Q (WB), although they accumulated at normal levels   
upon expression of AFG3L2 or AFG3L2
E575Q (PS) (Fig. 4 B). 
Consistently, the analysis of mitochondrial morphology in these 
cell lines revealed fragmentation of the mitochondrial network 
in the majority of cells expressing AFG3L2
E408Q (WB) (Fig. 4, 
C and D). In contrast, expression of AFG3L2 of AFG3L2
E575Q 
(PS) did not affect the morphology of mitochondria (Fig. 4,   
C and D). Expression of the dominant-negative AFG3L2 variant 
did  not  dissipate  the  mitochondrial  membrane  potential  in 
HEK293 cells (Fig. 4 E), nor was the oxygen consumption of 
HEK293 cells impaired (Fig. 4 F). However, similar to m-AAA 
protease–deficient MEFs, we observed a reduced RCR in cells 
expressing AFG3L2
E408Q (WB) (Fig. 4 F), suggesting an impaired 
energy metabolism under conditions of high energy demand. We 
conclude from these experiments that expression of a dominant-
negative variant of AFG3L2 and depletion of m-AAA protease 
subunits by RNAi similarly affect mitochondrial morphology 
and OPA1 processing.
OMA1 mediates OPA1 processing in the 
absence of m-AAA proteases
Our results suggest that an unidentified protease mediates pro-
cessing and degradation of the long OPA1 isoforms in m-AAA 
protease–deficient cells. Notably, lack of paraplegin (Fig. 3 A), 
PARL, or HtrA2/Omi did not stabilize L-OPA1 in the absence 
of AFG3L1 and -2 (Fig. S3 A). Furthermore, concomitant 
down-regulation of AFG3L1 and -2 with YME1L1 or LON did 
not rescue long OPA1 isoforms (Fig. S3 B). To restrict the num-
ber of possible proteases involved in this process, we incubated 
AFG3L1/AFG3L2-deficient MEFs expressing v1 with different 
protease inhibitors and monitored the accumulation of Flag-
tagged v1 and endogenous OPA1 by immunoblotting (Fig. 5 A). 
The stability of OPA1 was not affected upon incubating cells 
with pepstatin A, E-64d, or the broad-spectrum serine protease   
inhibitor Pefabloc (Fig. 5 A). In contrast, o-phenanthroline   
(o-phe), a membrane-permeable metalloprotease inhibitor, stabi-
lized v1, resulting in the accumulation of the long as well as the 
precursor form of OPA1 (Fig. 5 A). This is consistent with previ-
ous experiments on CCCP-induced OPA1 processing (Ishihara 
et al., 2006). Similarly, the proteasome inhibitor MG132 stabi-
lized v1 in AFG3L1/AFG3L2-depleted cells (Fig. 5 A). Thus, 
OPA1 levels in mitochondria depend critically on the activity of 
partial restoration of the tubular mitochondrial network upon 
expression of this variant in AFG3L1/AFG3L2-depleted cells 
(Fig. 3 B). We conclude from these experiments that turnover, 
as well as cleavage, of OPA1 at S1 is enhanced upon down-
regulation of m-AAA protease subunits.
Respiratory activity of m-AAA  
protease–deficient mitochondria
Disruption  of  the  mitochondrial  membrane  potential  and   
decreased ATP levels within mitochondria have been shown to   
induce processing of OPA1 (Duvezin-Caubet et al., 2006; 
Baricault et al., 2007). Respiratory chain deficiencies have recently 
been reported in brain mitochondria of Afg3l2
/ mice (Maltecca 
et al., 2008). Therefore, we assessed the formation of the mito-
chondrial membrane potential in cells depleted of m-AAA protease 
subunits using the membrane potential–dependent fluorescent dye 
JC-1 (Fig. 3 E). Whereas fluorescence dropped upon dissipation 
of the membrane potential by carbonyl cyanide m-chlorophenyl 
hydrazone (CCCP), the membrane potential was maintained upon 
depletion of m-AAA protease subunits (Fig. 3 E). Similarly, TMRE 
(tetramethylrhodamine, ethyl ester) measurements in Afg3l2
/ 
MEFs grown on glucose or galactose did not reveal an impaired 
membrane potential (Fig. S2).
In subsequent experiments, we measured oxygen con-
sumption in MEFs lacking m-AAA protease subunits to evalu-
ate  phosphorylating  respiration  with  endogenous  substrates. 
Down-regulation of AFG3L1 and -2 did not significantly affect 
oxygen consumption, irrespective of the presence of paraple-
gin (Fig. 3 F). However, respiration was significantly increased 
upon inhibition of the mitochondrial F1FO-ATP synthase with 
oligomycin, suggesting a higher proton leakage under condi-
tions of membrane hyperpolarization (Fig. 3 F). In m-AAA 
protease–depleted cells, we also observed a small but signifi-
cant decrease of the maximum respiratory capacity, which was 
measured under uncoupled conditions (Fig. 3 F). Accordingly, 
the ratio of uncoupled respiration and oligomycin-inhibited 
respiration, which is the respiratory control ratio (RCR), was 
reduced to 50% when AFG3L1 and -2 were down-regulated 
(Fig. 3 F). The loss of paraplegin did not further decrease the 
RCR (Fig. 3 F). These results indicate that the capacity of the 
oxidative phosphorylation system to supply ATP under condi-
tions of high energy demand is limited in the absence of the   
m-AAA protease. However, under normal conditions, respiration 
was not impaired upon down-regulation of m-AAA protease 
subunits, suggesting that AFG3L1 and -2 directly affect mito-
chondrial fusion.
A dominant-negative mutant of AFG3L2
To substantiate the role of the m-AAA protease for OPA1 pro-
cessing, we generated mutant variants of AFG3L2, in which 
glutamate 408 within the Walker B (WB) motif of the AAA   
domain or glutamate 575 within the proteolytic site (PS) were 
replaced by glutamine (WB, E408Q; PS, E575Q). Although 
glutamate 575 is essential for proteolytic activity, glutamate 408 
is conserved within AAA+ ATPases and is required to activate a 
water molecule for nucleophilic attack on bound ATP. AAA+ 
ATPases harboring a corresponding mutation in the WB motif 1029 Control of OPA1 by m-AAA protease and OMA1 • Ehses et al.
Figure 4.  Expression of dominant-negative AFG3L2
E408Q inhibits cell proliferation and impairs mitochondrial morphology and OPA1 processing.  
(A) Growth of cells expressing AFG3L2 (L2 WT), AFG3L2
E575Q (L2 PS), or AFG3L2
E408Q (L2 WB). Graphs represent means ± SD of three independent experi-
ments. (B) Immunoblot analysis of FlpIn T-REx 293 cells expressing AFG3L2 variants. Cell lysates were analyzed 24 h after the addition of tetracycline 
using antibodies directed against OPA1, AFG3L2, and SLP-2. (C and D) Mitochondrial morphology in cells expressing AFG3L2 variants. >100 cells were 
scored. WT, AFG3L2; PS, AFG3L2
E575Q; WB, AFG3L2
E408Q. (E) Membrane potential in cells expressing AFG3L2 (WT) or AFG3L2
E408Q (WB). (F) Oxygen 
consumption in cells expressing AFG3L2 (WT) or AFG3L2
E408Q (WB) measured as in Fig. 3 F. Error bars represent the means ± SD of a minimum of three 
independent experiments (***, P < 0.001). Bars, 10 µm.JCB • VOLUME 187 • NUMBER 7 • 2009   1030
Figure 5.  OMA1 degrades OPA1 in AFG3L1/AFG3L2-deficient MEFs. (A) Stability of OPA1 and OPA1 variant 1 in the presence of different protease 
inhibitors. Flag-tagged OPA1 variant 1 was expressed in MEFs that were subsequently depleted of AFG3L1 (L1) and AFG3L2 (L2). After 48 h, MEFs were 
incubated for 5 h with pepstatin A, E-64d, Pefabloc SC, o-phe, or MG132, and cell lysates were analyzed by immunoblotting with -Flag, -OPA1, and 
–complex II. p, OPA1 precursor; b, long OPA1 isoform; e, short OPA1 isoform. (B) Localization of OMA1 to mitochondria. Fluorescence microscopy of 
MEFs expressing murine OMA1 harboring a C-terminal GFP tag. Mitochondria were stained with MitoTracker red CMXRos, whereas the ER was detected 1031 Control of OPA1 by m-AAA protease and OMA1 • Ehses et al.
mitochondrial network after expression of a mitochondrially 
targeted DsRed variant in these cells (Fig. 5, E and F). Deple-
tion of OMA1 did not significantly affect mitochondrial mor-
phology in the presence of the m-AAA protease but restored the 
tubular network in AFG3L1/AFG3L2-deficient MEFs (Fig. 5, E 
and F). Electron micrographs revealed a normal, lamellar cris-
tae morphology of mitochondria lacking both the m-AAA pro-
tease and OMA1 (Fig. 5 E). These findings substantiate our 
conclusion that the m-AAA protease regulates mitochondrial 
fusion via OPA1 and demonstrate that OMA1 is epistatic to the 
m-AAA protease.
To further define the functional interrelationship of OMA1 
and the m-AAA protease, we assessed the assembly of m-AAA 
proteases in OMA1-depleted mitochondria by blue-native gel 
electrophoresis (Fig. S4 B). Down-regulation of OMA1 did not 
affect the formation of the proteolytic complexes containing 
AFG3L2  and/or  -1.  Moreover,  depletion  of  OMA1  did  not   
interfere with the maturation of AFG3L1 or -2 (Fig. 5 C and 
Fig. S5), which occurs autocatalytically upon import into mito-
chondria  (Koppen  et  al.,  2009).  Similarly,  processing  of  an 
OMA1 variant carrying a C-terminal myc tag was not impaired 
in mitochondria depleted of AFG3L1 and -2 (Fig. S4 C).
Tissue-specific destabilization of L-OPA1  
in Afg3l2
/ mice
Mutations  in  the  m-AAA  protease  subunits  paraplegin  and 
AFG3L2  cause  neurodegeneration  in  human,  but  molecular   
details of the pathogenesis are currently not understood. Our 
experiments revealed an at least partially redundant function of 
AFG3L1 and -2 for mitochondrial fusion in MEFs (Fig. 1). 
However, as AFG3L1 is a pseudogene in humans (Kremmidiotis   
et al., 2001) and is expressed at low levels in the mouse brain 
(Koppen et al., 2007; Martinelli et al., 2009), it is conceivable 
that the regulation of OPA1 processing by the m-AAA protease 
is of potential pathogenic relevance. To examine whether the 
loss of AFG3L2 impairs OPA1 cleavage in vivo, we monitored 
OPA1 processing in mitochondria isolated from tissues of a   
recently established Afg3l2
/ mouse line (Maltecca et al., 2008). 
The abundance of individual OPA1 isoforms varies in different 
tissues, as previously described (Fig. 6 A; Akepati et al., 2008). 
In  the  absence  of AFG3L2,  L-OPA1  isoforms  accumulated   
at strongly reduced levels in the brain, heart, and kidney, dem-
onstrating that the stability of L-OPA1 depends on AFG3L2   
in vivo. Notably, deletion of Afg3l2 hardly affected OPA1 isoforms 
in the liver (Fig. 6 A), which is consistent with a compensatory 
effect of AFG3L1, which is expressed at higher levels relative to 
AFG3L2 in the liver (Koppen et al., 2007).
To analyze whether depletion of OMA1 can suppress dele-
terious effects of the loss of the Afg3l2 gene, we monitored OPA1 
26-S proteasomes and an unknown metallopeptidase. It is con-
ceivable that inhibition of the general mitochondrial processing 
peptidase  causes  the  accumulation  of  the  precursor  form  of 
OPA1 within mitochondria in the presence of o-phe. Similarly, 
26-S proteasomes may degrade newly synthesized OPA1 in the 
cytosol before import into mitochondria rather than mediating 
the turnover of preexisting mitochondrial OPA1. In agreement 
with this hypothesis, MG132 did not stabilize v1S1 in the   
absence of AFG3L1 and -2 when cytosolic protein synthesis 
was inhibited by CHX (Fig. S3 C). Thus, the inhibitor experi-
ments did not allow us to identify proteases controlling the   
stability of L-OPA1 within mitochondria.
We have previously identified Oma1 in the inner mem-
brane of yeast mitochondria as a metallopeptidase, whose activ-
ity overlaps with the m-AAA protease (Oma1 for overlapping 
activity with m-AAA protease 1; Käser et al., 2003). Oma1 is 
conserved in evolution with homologous proteases present in 
vertebrates. However, human OMA1 has been localized to the 
ER membrane (Bao et al., 2003). To reexamine the subcellular 
localization of OMA1, we expressed an OMA1 variant harbor-
ing a C-terminal GFP domain in MEFs (Fig. 5 B). OMA1-GFP 
was exclusively localized to mitochondria and not detected in 
the ER membrane (Fig. 5 B). Similarly, a tubular mitochondrial 
network was visible in immunofluorescence experiments after 
transient expression of an OMA1 variant harboring a C-terminal 
Flag tag (unpublished data). We conclude that OMA1, as yeast 
Oma1, is localized in mitochondria.
To examine whether OMA1 affects OPA1 processing in the 
mitochondrial inner membrane, we used three different oligo-
nucleotides directed against Oma1 for RNAi. Quantitative 
RT-PCR experiments revealed efficient down-regulation of Oma1 
transcripts by >80% (Fig. S4 A). Depletion of OMA1 slightly   
reduced the level of OPA1 isoforms c and e, which are generated 
by S1 cleavage and accumulate at low levels under these condi-
tions in MEFs (Fig. 5 C). However, we observed a significant sta-
bilization of L-OPA1 in AFG3L1/AFG3L2-deficient MEFs upon 
down-regulation of OMA1, whereas transfection of the cells with 
scrambled oligonucleotides had no effect (Fig. 5 C).
We monitored OPA1 processing directly after transient ex-
pression of the Flag-tagged OPA1 variant v1 in MEFs (Fig. 5 D). 
In the presence of AFG3L1 and -2, Flag-tagged L-OPA1 accumu-
lated in OMA1-depleted cells (Fig. 5 D), indicating that OMA1 is 
able to cleave overexpressed OPA1. In contrast, in the absence of 
AFG3L1 and -2, down-regulation of OMA1 stabilized L-OPA1, 
demonstrating that OMA1 mediates turnover and increased OPA1 
processing in the absence of the m-AAA protease (Fig. 5 D).
OPA1  isoforms  accumulated  virtually  as  in  wild-type 
(WT) cells in MEFs depleted of both OMA1 and the m-AAA 
protease.  Therefore,  we  examined  the  morphology  of  the   
using an antiserum directed against calnexin. (C) Immunoblot analysis of MEFs transfected with siRNAs directed against AFG3L1 and -2 and OMA1 or 
scrambled siRNA (Scr) using specific antisera recognizing OPA1, AFG3L1 and -2, and the 70-kD subunit of complex II (CII). Three different siRNAs directed 
against OMA1 were used. (D) Immunoblot analysis of MEFs transfected with siRNAs directed against AFG3L1/AFG3L2 and OMA1 and Flag-tagged OPA1 
splice variant 1 (v1). Cell lysates were analyzed 3 d after transfection by SDS-PAGE and immunoblotting using -Flag, -AFG3L1, -AFG3L2, -OPA1, and 
–complex II antibodies. (E) Mitochondrial morphology in MEFs transfected with AFG3L1/AFG3L2 and OMA1 siRNA was visualized by expression of mito-
DsRed (left). Mitochondrial ultrastructure was analyzed by electron microscopy. (F) Quantification of mitochondrial morphology. >150 MEFs were scored in 
each immunofluorescence experiment. Bars represent means ± SD of three independent experiments (**, P < 0.01). Bars: (B) 10 µm; (E) 0.2 µm.
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OPA1 processing and results in mitochondrial fragmentation 
(Duvezin-Caubet et al., 2006; Baricault et al., 2007). There-
fore, we compared the accumulation of OPA1 isoforms in a 
human osteosarcoma cell line containing (WT) or lacking 
mitochondrial DNA (mtDNA; 
0; Fig. 7 A). Although long 
and short OPA1 isoforms accumulated in these cells in the 
presence of mtDNA, short isoforms accumulated in 
0 cells 
(Fig. 7 A). Strikingly, long OPA1 isoforms were detected   
after RNAi-mediated down-regulation of OMA1, suggesting 
that the loss of mtDNA induces OPA1 cleavage by OMA1.
OPA1 is converted into short isoforms upon dissipation 
of m with the uncoupler CCCP or upon inhibition of the 
F1FO-ATP synthase with oligomycin (Fig. 7, B and C; Duvezin-
Caubet et al., 2006; Ishihara et al., 2006). Down-regulation of 
OMA1 before the addition of CCCP or oligomycin signifi-
cantly stabilized long OPA1 isoforms, indicating that OPA1 
processing is mediated by OMA1 under both conditions (Fig. 7, 
B and C). In conclusion, these experiments identify OMA1 as 
the protease responsible for the inducible cleavage of OPA1 at 
processing site S1.
processing and mitochondrial morphology in Afg3l2
/ MEFs 
(Fig. 6, B–D). Deletion of Afg3l2 only slightly affected cleavage 
of OPA1 in MEFs grown on glucose-containing medium, most 
likely because of the presence of AFG3L1 in these cells (Fig. 6 B). 
However, L-OPA1 was absent in Afg3l2
/ MEFs grown in   
the presence of galactose, i.e., conditions with an increased   
demand for mitochondrial respiratory function (Fig. 6 B). This 
was accompanied by a fragmentation of the mitochondrial net-
work in the majority of these cells (Fig. 6, C and D). Depletion   
of OMA1 in immortalized Afg3l2
/ MEFs, cultured either in 
glucose-  or  galactose-containing  medium,  stabilized  L-OPA1, 
providing further evidence that OMA1 mediates OPA1 process-
ing if the function of the m-AAA protease is impaired (Fig. 6 E).
Mitochondrial dysfunction induces OPA1 
processing by OMA1
We next examined whether OMA1 also cleaves OPA1 under 
other cellular conditions known to induce OPA1 processing. 
Current models suggest that a dysfunction of mitochondria 
accompanied by decreased mitochondrial ATP levels stimulates 
Figure 6.  Impaired OPA1 processing in Afg3l2
/ mice. (A) Immunoblot analysis of mitochondria isolated from the brain, liver, heart, and kidney of WT 
(L2
+/+) or Afg3l2
/ (L2
/) mice using antisera directed against OPA1 and the 70-kD subunit of complex II (CII). (B) Immunoblot analysis of OPA1 in WT 
or Afg3l2
/ primary MEFs grown in the presence of glucose or galactose. (C and D) Mitochondrial morphology in WT or Afg3l2
/ cells was visualized 
by expression of a mitochondrially targeted GFP. >100 cells were scored. Bas represent means ± SD of three independent experiments. (E and F) Stabiliza-
tion of long OPA1 isoforms in Afg3l2
/ MEFs grown in glucose or galactose upon down-regulation of OMA1. Immunoblot analysis was performed using 
specific antisera recognizing OPA1 and complex II. Scr, scrambled RNAi. Bar, 10 µm.1033 Control of OPA1 by m-AAA protease and OMA1 • Ehses et al.
not a functional impairment of one m-AAA protease subunit   
affects the morphology of the mitochondrial network. Notably, 
the m-AAA protease subunit predominantly expressed in the 
mouse brain is AFG3L2, whereas AFG3L1 is only present at 
lower levels (Koppen et al., 2007; Martinelli et al., 2009). This 
explains severe neurological defects (Maltecca et al., 2008) and 
cerebellar degeneration in mice with reduced levels of AFG3L2-
containing m-AAA isoenzymes (Martinelli et al., 2009), which   
is  reminiscent  of  patients  with  heterozygous  mutations  in   
human AFG3L2 (Cagnoli et al. 2008. Annual meeting of the 
American Society of Human Genetics. Abstr. 1501; DiBella   
et al. 2008. Annual meeting of the American Society of Human 
Genetics. Abstr. 216).
Whereas mitochondrial fusion depends on the presence of 
either AFG3L1 or -2, the third m-AAA protease subunit para-
plegin is not required to maintain a reticulated mitochondrial 
network. Deletion of Spg7-encoding paraplegin did not affect 
mitochondrial  morphology  in  MEFs.  Moreover,  phenotypes   
observed upon down-regulation of AFG3L1 and -2 were not 
worsened in paraplegin-deficient cells. However, it should be 
noted that an efficient depletion of AFG3L1 and -2 inactivates 
paraplegin that only exists in heterooligomeric complexes with 
AFG3L1 and -2 (Koppen et al., 2007). Thus, it is conceivable 
that paraplegin-containing isoenzymes may control mitochon-
drial morphology in cells expressing limiting levels of AFG3L1 
and -2. This may explain the cell type–specific axonal degener-
ation associated with mutations in paraplegin both in mouse and 
human (Casari et al., 1998; Ferreirinha et al., 2004).
The m-AAA protease controls mitochondrial fusion via 
OPA1 (Fig. 8). The loss of AFG3L2 in various tissues of the 
mouse, down-regulation of AFG3L1 and -2 in MEFs, or the   
expression of a dominant-negative AFG3L2 variant in human 
cells decreases OPA1 stability and results in an increased pro-
cessing and turnover of long OPA1 isoforms. This causes frag-
mentation of the tubular mitochondrial network, which is at 
least  partially  restored  upon  expression  of  an  OPA1  variant 
lacking the cleavage site S1. Thus, our experiments link, for the 
first time, the function of AFG3L1 and -2 to OPA1 in vivo.
Strikingly, inactivation or loss of the m-AAA protease 
does not result in the accumulation of long OPA1 isoforms, as 
predicted by experiments in yeast (Duvezin-Caubet et al., 2007), 
but decreases their stability. The accelerated cleavage of OPA1 
in the absence of the m-AAA protease is mediated by OMA1,   
a new member of a conserved and widespread family of mem-
brane-bound M48 metallopeptidases. We have previously iden-
tified yeast Oma1 in the mitochondrial inner membrane as a 
peptidase that can substitute for the function of the m-AAA pro-
tease  during  degradation  of  a  misfolded  membrane  protein 
(Käser et al., 2003). Similarly, synthetic growth defects have 
been observed when mutations in the bacterial AAA protease 
FtsH were combined with mutations in HtpX, which is a distant 
homologue of OMA1, indicating overlapping proteolytic activi-
ties (Shimohata et al., 2002). In agreement with these findings, 
we demonstrate in this study that mammalian OMA1, similar to 
the m-AAA protease, can cleave OPA1. The substrate specific-
ity of OMA1 is distinct from yeast Oma1, which cleaves neither 
OPA1 when expressed in yeast nor the yeast OPA1 homologue 
Discussion
Mutations in m-AAA protease subunits cause neurodegenera-
tion, but pathogenic mechanisms remain enigmatic. Our results 
identify the m-AAA protease as a novel regulator of mitochon-
drial membrane fusion and cristae morphology, suggesting that 
m-AAA protease–associated diseases may represent a group of 
neurological disorders caused by deficiencies in mitochondrial 
dynamics. Murine AFG3L1- and AFG3L2-containing m-AAA 
protease isoenzymes exert at least partially overlapping activi-
ties during membrane fusion. Therefore, the relative expression 
of AFG3L1 and -2 in different tissues will determine whether or 
Figure 7.  Mitochondrial dysfunction induces OPA1 processing by OMA1. 
(A) OMA1 stabilizes long OPA1 isoforms in the absence of mtDNA. Immuno-
blot analysis of human osteosarcoma cells (143B) using specific antisera 
recognizing OPA1 and the 70-kD subunit of complex II (CII). Cells lack-
ing mtDNA (
0) were transfected with OMA1-specific or scrambled (Scr) 
siRNA and compared with parental cells containing mtDNA (WT). Cell 
lysates were analyzed 72 h after transfection. (B and C) Stabilization of 
long OPA1 isoforms against CCCP (B)- and oligomycin (OLG; C)-induced 
processing in OMA1-depleted MEFs. MEFs transfected with OMA1-specific   
or scrambled siRNA were incubated after 48 h with 20 µM CCCP or after   
60 h with 2 µM oligomycin for the indicated time periods. Cell lysates were   
analyzed by SDS-PAGE and immunoblotted with antibodies directed against 
OPA1 and complex II.JCB • VOLUME 187 • NUMBER 7 • 2009   1034
preceding its proteolytic cleavage. A similar nonproteolytic   
activity has been assigned to the m-AAA protease during the 
biogenesis of yeast cytochrome c peroxidase (Tatsuta et al., 
2007). In yeast, the ATP-dependent mitochondrial import motor 
was proposed to regulate Mgm1 processing by the rhomboid 
protease in response to mitochondrial ATP levels in a process 
termed alternative topogenesis (Herlan et al., 2004). Constitu-
tive OPA1 processing might be regulated in a similar manner. 
Notably, membrane dislocation could also be affected by an al-
tered phospholipid composition of mitochondrial membranes, 
which has recently been observed in yeast mitochondria lacking 
the m-AAA protease (Osman et al., 2009). Several observations 
indeed suggest that OMA1 can cleave OPA1 in the presence of 
the m-AAA protease. Depletion of OMA1 in human osteo-
sarcoma cells or in MEFs cultured in galactose-containing medium 
leads to the disappearance of OPA1 isoforms c and e, indicating 
that OMA1 can affect constitutive OPA1 processing at S1. 
Moreover, OMA1 is required for S1 cleavage of OPA1 over-
expressed in MEFs. However, an OMA1-like peptidase appears 
to be absent in Caenorhabditis elegans and Drosophila melano-
gaster, although mitochondrial morphology depends on OPA1 
in  both  organisms.  In  addition,  neither  down-regulation  nor 
overexpression of OMA1 affects mitochondrial morphology in 
MEFs, suggesting that OMA1 is dispensable for the balanced 
formation of long and short OPA1 isoforms.
According to the second scenario, constitutive and stress-
induced OPA1 processing are mediated by two distinct pep-
tidases,  which  differ  in  their  enzymatic  properties:  the 
ATP-dependent m-AAA protease ensures the balanced accumu-
lation of long and short isoforms under constitutive conditions, 
whereas  OMA1  acting  in  an ATP-independent  manner  com-
pletely  converts  long  OPA1  isoforms  into  short  forms  under 
stress conditions. In agreement with a role of the m-AAA prote-
ase as a processing enzyme under normal conditions, reconstitu-
tion experiments in yeast demonstrate that AFG3L1 and -2 can 
cleave OPA1 in a heterologous environment (Duvezin-Caubet et 
al., 2007). Moreover, paraplegin binds OPA1 when overexpressed 
and stimulates OPA1 processing (Ishihara et al., 2006). OPA1 
processing by ATP-dependent and -independent peptidases under 
different physiological conditions would resolve the apparent 
Mgm1 (Duvezin-Caubet et al., 2007). Therefore, differences in 
substrate recognition by OMA1-like peptidases may explain 
why the loss of the m-AAA protease is not accompanied by in-
creased OPA1 processing in yeast. Interestingly, mitochondrial 
rhomboid proteases, although highly conserved, also differ in 
their ability to cleave OPA1. Both yeast Pcp1 and its mammalian 
homologue PARL mediate processing of Mgm1, but neither   
of them cleave OPA1 when expressed in yeast (Duvezin-Caubet 
et al., 2007).
The regulation of OPA1 stability and processing at site   
S1 by two peptidases raises the question of which peptidase   
mediates constitutive and stress-induced OPA1 cleavage. Our   
experiments reveal that OMA1 promotes OPA1 processing if 
mitochondrial  activities  are  impaired  (Fig.  8).  The  loss  of 
mtDNA, dissipation of m, or a decrease of mitochondrial 
ATP levels induces OPA1 processing by OMA1. The molecular 
mechanism of OMA1 activation under stress conditions remains 
to  be  determined.  Mitochondrial  dysfunction  may  alter  the   
accessibility of the S1 cleavage site in OPA1, allowing stress-
induced  cleavage  by  OMA1. Alternatively,  stress  conditions 
may increase the proteolytic activity of OMA1 itself. It is also 
possible that stress conditions lower mitochondrial ATP levels 
and thereby m-AAA protease activity, resulting in the accumu-
lation of an activator of OMA1.
In contrast to the stress-induced OPA1 cleavage, constitu-
tive cleavage of OPA1 during mitochondrial biogenesis affects 
only  a  subset  of  the  newly  imported  OPA1  molecules  and   
results in an approximately equimolar accumulation of long and 
short isoforms. As both forms are required for mitochondrial 
fusion (Song et al., 2007), their balanced formation is critical 
for the maintenance of the mitochondrial network. Although 
our experiments identify OMA1 as the peptidase responsible 
for stress-induced OPA1 cleavage, two possibilities must be 
considered for constitutive OPA1 processing.
According to the first scenario, OMA1 is responsible for 
both constitutive and induced OPA1 cleavage. However, the 
m-AAA protease is required to stabilize long OPA1 isoforms and 
inhibit OMA1 activity under normal conditions, possibly exert-
ing functions beyond a role as a processing enzyme. These may 
include the ATP-dependent membrane dislocation of OPA1   
Figure  8.  Two  peptidases  regulate  OPA1 
cleavage at S1. Newly imported OPA1 mol-
ecules are processed by the mitochondrial pro-
cessing peptidase (MPP) in the matrix space 
(Ishihara et al., 2006). The stability of long 
OPA1 isoforms depends on m-AAA protease 
isoenzymes containing AFG3L1 and -2, which 
ensure  the  balanced  formation  of  long  and 
short OPA1 isoforms upon S1 cleavage and 
maintain mitochondrial fusion. The m-AAA pro-
tease itself may act as a processing peptidase   
for  OPA1  or  promote  constitutive  cleavage   
by OMA1. At decreased mitochondrial ATP 
levels,  after  dissipation  of  m,  or  in  the 
absence of mtDNA, OMA1 promotes stress-
induced  OPA1  processing,  resulting  in  the 
complete conversion of long OPA1 isoforms to 
short variants. Constitutive cleavage of OPA1 
at site 2 is not depicted. MTS, mitochondrial 
targeting sequence.1035 Control of OPA1 by m-AAA protease and OMA1 • Ehses et al.
Fluorescence  images  were  acquired  using  a  camera  (CoolSNAP  HQ/
ICX285; Sony) and a Plan-Apochromat N 60× NA 1.42 oil objective 
(Olympus). Image stacks were deconvoluted with the SoftWoRx Imaging 
Suite  (Applied  Precision).  Image  files  were  further  processed  with  the 
CorelDRAW 11 Graphics Suite software (Corel). For colocalization of 
OMA1-GFP  and  mitochondria,  we  stained  cells  with  MitoTracker  red 
CMXRos (Invitrogen) and used a microscope (Eclipse E600; Nikon) and 
a Plan-Apochromat A 60× NA 1.40 oil objective (Nikon). Images were 
acquired with a confocal microscope (Radiance 2100; Bio-Rad Laborato-
ries). For detection of the ER, cells were stained with an antiserum directed 
against calnexin and examined using an imaging station (Eclipse TE2000-S 
[Nikon] + CARV II [BD]) and a Plan-Apochromat VC 100× NA 1.40 oil 
objective (Nikon), and images acquired using a camera (QuantEM 512 
SC; Photometrics) and deconvoluted with MetaMorph software (MDS Analyti-
cal Technologies).
Transmission electron microscopy
MEFs were plated on glass coverslips, transfected with siRNA, and after 
48 h, flat embedded (Merkwirth et al., 2008). Ultrathin sections (60–70 nm) 
were cut and mounted on pioloform-coated copper grids (Plano). Sections 
were stained with lead citrate and uranyl acetate and viewed with a trans-
mission electron microscope (JEM-2100; JEOL Ltd.) operated at 80 kV.   
Micrographs were taken using a charge-coupled device camera (Erlang-
shen ES500W; Gatan Inc.).
Polarographic measurements
Respiration of intact cells was measured at 37°C with a Clark-type electrode 
oxygraph (Hansatech Inc.). 2.5 × 10
6 cells were assayed in 250 mM sac-
charose, 20 mM Hepes, pH 7.4, 10 mM KH2PO4, 4 mM MgCl2, 1 mM 
EDTA, 5 mM glucose, 2 mM pyruvate, and 4 mM glutamate. After recording 
endogenous respiration, ATP synthase was inhibited with 2 µM oligomycin 
followed by uncoupling of oxidative phosphorylation using CCCP with con-
centrations of 250–750 nM. Cellular respiration was inhibited with 2 mM 
KCN and was corrected to KCN-insensitive respiration.
Inhibitor experiments
To induce SIMH, MEFs were exposed to 1 µM CHX for 3 h 2–3 d after 
transfection with siRNAs and plasmids and were incubated for 5 h with the 
following protease inhibitors: 5 µM MG132, 0.5 mM o-phe, 50 µM pep-
statin A, 0.5 mM Pefabloc SC, and 50 µM E-64d. To induce OPA1 cleav-
age, MEFs were treated either with 2 µM oligomycin 60 h after transfection 
or with 20 µM CCCP 48 h after transfection.
Antibodies
Polyclonal antibodies directed against murine m-AAA protease subunits 
were described previously (Koppen et al., 2007). An antiserum recogniz-
ing murine LON was provided by C. Suzuki (University of Medicine and 
Dentistry of New Jersey, Newark, NJ). The following commercially avail-
able  antibodies  were  used:  -OPA1  (Invitrogen),  -Flag  M2  (Sigma-
  Aldrich),  –SLP-2  (GenWay  Biotech  Inc.),  -calnexin  (Stressgen),  and 
–complex II (Invitrogen).
Online supplemental material
Fig. S1 shows the mitochondrial morphology in paraplegin-deficient MEFs. 
Fig. S2 demonstrates the maintenance of the mitochondrial membrane po-
tential in Afg3l2
/ mitochondria using TMRE fluorescence. Fig. S3 shows 
the stability of OPA1 in AFG3L1/AFG3L2-deficient cells lacking various 
mitochondrial proteases and the effect of an inhibition of cytosolic protein 
synthesis on OPA1 isoforms accumulating in m-AAA protease–deficient 
MEFs  in  the  presence  of  MG132.  Fig.  S4  shows  the  quantification  of 
OMA1 mRNA levels in MEFs after down-regulation of OMA1 by RNAi, 
demonstrates the assembly of AFG3L2 and -1 in m-AAA protease com-
plexes in OMA1-deficient mitochondria by blue-native–PAGE analysis, and 
reveals normal processing of OMA1 in m-AAA protease–deficient mito-
chondria. Fig. S5 shows the accumulation of AFG3L1 and -2 in OMA1-
  deficient MEFs. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200906084/DC1.
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caveat of previous studies suggesting that processing of OPA1 
may involve the m-AAA protease but is accelerated at decreased 
mitochondrial ATP levels (Duvezin-Caubet et al., 2006, 2007; 
Ishihara et al., 2006; Baricault et al., 2007). It also offers an   
attractive possibility for regulation: low ATP levels may impair 
membrane  dislocation  of  OPA1  possibly  mediated  by  the   
m-AAA protease and thereby make OPA1 accessible for OMA1 
cleavage under stress conditions. Clearly, further experiments are 
required to define the relative contribution of the m-AAA prote-
ase and OMA1 to constitutive OPA1 cleavage, which may also 
depend on relative expression levels in different tissues and cell 
types.  Regardless,  the  identification  of  proteases  involved  in 
OPA1 processing now allows us to assess the relevance of an im-
paired OPA1 cleavage and mitochondrial fragmentation for the 
maintenance of cellular functions and for various disease states.
Materials and methods
Generation of immortalized MEFs lines
All animal procedures were performed according to protocols approved 
by the Institutional Animal Care and Use Committee. The generation of   
Spg7
/ mice (Ferreirinha et al., 2004) and Afg3l2
Emv66/Emv66 genetic   
characterization  (Maltecca  et  al.,  2008)  were  previously  described.   
Afg3l2
Emv66/Emv66 mice were provided by G. Cox (The Jackson Laboratory, 
Bar Harbor, ME). Primary MEFs were established from embryonic day (E) 
14.5 Spg7
/ or E13.5 Afg3l2
Emv66/Emv66 and littermate WT embryos and 
immortalized by SV40 transformation. MEFs were cultured in DME containing 
4.5 g/liter glucose and supplemented with 10% FCS. When specified, 
MEFs were cultured in DME with 6 mM galactose. The human osteosarcoma-
derived cell line 143B and its 
0 derivative were provided by R. Wiesner 
(University of Cologne, Cologne, Germany) and grown in medium supple-
mented with 50 µg/ml uridine.
Down-regulation of m-AAA protease subunits and OMA1
RNAi-mediated knockdown of paraplegin, AFG3L1 and -2, and OMA1 was 
performed using specific Stealth RNAi and the nontargeting Stealth RNAi 
negative control (Invitrogen). The sequences are 5-GCGCGUCAUUGCUG-
GUACUGCUAAA-3 for paraplegin, 5-CCUGCCUCCGUACGCUCUAU-
CAAUA-3 for AFG3L2, 5-GCGAAACCAUGGUGGAGAAGCCAUA-3 
for AFG3L1, and 5-GGAUACAGUCAAAGUUGCAGAGUA-3, 5-AGUU-
CUCAGAGAGUCUUCAUGGCUA-3,  and  5-GCUUCUUGGUCUGAGUG-
CAUUUGGA-3 for murine OMA1. For human OMA1, Stealth siRNAs with 
the sequences 5-TGGACTACTGCTTGCTGCAAAGGCT-3 and 5- TGGCA-
GCAAATGGAGTTCGTTGATA-3 were used. 10–20 nM of each siRNA was 
transfected twice with Lipofectamine (Invitrogen). Down-regulation was moni-
tored by immunoblot analysis of cell lysates generated after 2 d if not indi-
cated otherwise.
Expression of AFG3L2 variants and OMA1
Human Afg3l2 was cloned into pcDNA5/FRT/TO, and mutations were   
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